



CLINICAL
TRIALS
TRANSFORMATION
INITIATIVE

June 12, 2017

Use of RWD in Pre-Study Planning and Study Set up:

A Health Plan Perspective

Kevin Haynes, PharmD, MSCE

HealthCore

Disclaimer

- The views and opinions expressed in this presentation are those of the individual presenter and do not necessarily reflect the views of the Clinical Trials Transformation Initiative.
- The presenter is an Employee of HealthCore a Research Subsidiary of Anthem. Salary support comes from grants and contracts:
 - PCORI Awards
 - FDA Sentinel

Anthem: A Health Benefits Leader

OVERVIEW & MEMBERSHIP

1 in 8 Americans





40 million
total medical members in
affiliated health plans

over 73 million
total lives served

1 in 12 births in the US

Q3 2016 Data



SUBSIDIARIES



*Anthem Blue States (14): California, Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri, Nevada, New Hampshire, New York, Ohio, Virginia, Wisconsin

HealthCore

- Real-World Evidence (RWE) development company
- 220 associates
- Offices in Wilmington, Delaware; Watertown & Andover, Massachusetts and Alexandria, Virginia
- Founded in 1996 through an asset purchase from BCBS of Delaware
- Acquired by WellPoint Health Networks in 2003
- WellPoint acquired by Anthem in 2004
- Acquired New England Research Institutes in 2017

Rapidly Evolving Landscape

National Frameworks for Evidence Generation



Implementation of a randomized controlled trial to improve treatment with oral AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF)

- **Direct mailer to health plan members and providers with Afib at high risk for stroke and no oral anticoagulant treatment**


ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness)

HealthCore has enrolled 239 members with additional outreach waves planned




HealthCore Integrated Research Environment

Directly Linking Claims with Other Data Sources



HealthCore Integrated Research Database



Claims Data Availability

63.9 million researchable lives total with medical eligibility

47.1* million researchable lives total with both medical & pharmacy eligibility


Millions with continuous eligibility for:

1 year:	32.3
2 years:	22.7
3 years:	16.5
4 years:	11.4


* Includes Carve-out Pharmacy Data

14.6 million lives with electronic outpatient laboratory result data

Data Integration Via Direct Linkage



Provider Locations* and Patient Density – All Potentially Eligible T2D Patients, A1c > 7%



*Includes only providers with 10 or more eligible patients

	Provider count
≥10 patients	1,882
≥15 patients	889
≥20 patients	480



Examples of Pre-Study Planning

ADAPTABLE Study Design

Patients with known ASCVD + ≥ 1 “enrichment factor”

Identified through EHR (computable phenotype) by CDRNs
Or by administrative claims (computable phenotype) by HPRNs

Patients contacted with trial information and link to e-consent;[†]
Treatment assignment will be provided directly to patient

ASA 81 mg QD

ASA 325 mg QD

Electronic follow-up: Every 3 or 6 months
Supplemented with EHR/CDM/claims data

Duration: Enrollment over 24 months;
maximum follow-up of 30 months

Primary endpoint:

Composite of all-cause mortality, hospitalization for MI, or hospitalization for stroke


Primary safety endpoint:

Hospitalization for major bleeding

[†] Participants without internet access will be consented and followed via a parallel system.

ClinicalTrials.gov: NCT02697916

Health Plan ADAPTABLE Outreach



Examples of HealthCore PCTs

Indication/TA	Number of Sites	Number of Patients	Basic Design
Endocrinology /Type 2 DM	742	6570	Pragmatic Clinical Trials comparing the Real-World Use of treatment of interest vs Standard of Care Cluster randomization by site or randomization between treatment options used
Allergy and Immunology /Severe Asthma	20	150	Registry comparing pre post outcomes of interest
Psychiatry/ MDD, Schizophrenia and BP1 Disorder	60	600	A Multicenter, Randomized, Pragmatic Trial to compare treatment of interest with treatment as usual
Respiratory/COPD	530	4500	Randomized Pragmatic Clinical Trial conducted in a community based setting comparing treatment of interest with standard of care

THANK YOU.



CLINICAL
TRIALS
TRANSFORMATION
INITIATIVE

Kevin Haynes

khaynes@healthcore.com

www.healthcore.com



www.ctti-clinicaltrials.org